China approves first-in-class monoclonal antibody for chronic hepatitis D treatment for

Get Involved
1

https://trial.medpath.com/news/4b235401339c3a48/china-approves-first-in-class-monoclonal-antibody-for-chronic-hepatitis-d-treatment

2 Likes
2

Dear @availlant,

What are your thoughts about this drug? Does this drug target HBSag efficiently. HuaHui company and my country have signed a deal. Officials agreed to fast-track Phase III trials to deliver the treatment to eligible patients quickly under strict monitoring in our country.